Ingrezza is approved for the treatment of tardive dyskinesia in adults [1]. It is the first and only medication specifically approved for this condition in the United States [2]. Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive, and purposeless movements [1].
How does Ingrezza work for tardive dyskinesia?
Ingrezza works by targeting VMAT2 (vesicular monoamine transporter type 2), a protein that regulates the transport of monoamines like dopamine [1][3]. By inhibiting VMAT2, Ingrezza reduces the amount of dopamine available at nerve terminals, which can help to lessen the involuntary movements associated with tardive dyskinesia [1][3].
What is the typical dosing for Ingrezza?
The recommended starting dose for Ingrezza is 40 mg once daily. After one week, the dose is typically increased to 60 mg once daily. For tardive dyskinesia, the dose may be further increased to 80 mg once daily after one week, and then to the target dose of 60 mg twice daily after another week [1].
Are there any side effects associated with Ingrezza?
Common side effects of Ingrezza include sleepiness, dry mouth, constipation, and headache [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How long does it take to see results with Ingrezza?
Many patients experience a reduction in tardive dyskinesia movements within two weeks of starting Ingrezza, with continued improvement observed over time [4].
How does Ingrezza compare to other treatments for tardive dyskinesia?
Ingrezza is the first and only FDA-approved medication specifically for tardive dyskinesia [2]. Before its approval, there were no specific FDA-approved treatments for this condition [2].
What is the patent status of Ingrezza?
Information on the specific patent expiration dates for Ingrezza can be found on DrugPatentWatch.com [5]. Patents for drugs are crucial for manufacturers as they provide market exclusivity.
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
What is the cost of Ingrezza?
The cost of Ingrezza can vary depending on insurance coverage and pharmacy pricing. Patients are encouraged to discuss financial assistance programs with their healthcare provider or the manufacturer.
---
Sources:
[1] https://www.ingrezza.com/
[2] https://www.prnewswire.com/news-releases/ingrezza-ncrx-is-now-the-first-and-only-fda-approved-drug-for-tardive-dyskinesia-103807244.html
[3] https://www.drugpatentwatch.com/drug/ingrezza
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1600679
[5] https://www.drugpatentwatch.com/